UNSPSC 51343113: Sorivudine

This classification denotes a dihydropyrimidine dehydrogenase inhibitor with the molecular formula C11H13BrN2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7VOZ162LV, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-, (e)- but generally known as sorivudine, which bears US NIH Compound Identifier 5282192. European Medicines Agency schedules Sorivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10605MIG.

UNSPSC 51343113 Sorivudine (Commodity) does not align with state and local procurement activity currently being tracked under this code. The recent opportunities posted against this code span naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic pharmaceuticals with OTC products—none of which are antiviral medications like sorivudine. The mismatch suggests either a classification error in the procurement databases or that this Commodity code does not reflect current buying patterns in state and local healthcare procurement.

The issuing bodies in the recent records include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota MMCAP). The geographic spread spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries (due July 26, 2023), the City of Tampa's sealed-bid procurement for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a 5 percent SLBE bid discount (due March 13, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with proposals due March 26, 2026. No current activity directly reflects sorivudine procurement at the state or local level.